$4 Million California Investment in "Killer' Cells Goes Awry

Twenty-two Percent Drop in Fate Therapeutics Stock Price Last Week

Aug 23, 2021

∙ Paid

Google chart

California’s stem cell agency last week received some less-than-good news about a $4 million investment it made three years ago involving “killer” cells and cancer.

The news came from Fate Therapeutics, which saw its stock price plummet 22 percent last Thursday and Friday. The decline was linked to disappointing results from clinical trials…

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.